| Literature DB >> 33190475 |
Charlotte Martin1, Luis E Gimenez2, Savannah Y Williams2, Yu Jing3, Yiran Wu3, Charlie Hollanders1, Olivier Van der Poorten1, Simon Gonzalez1, Kevin Van Holsbeeck1, Santo Previti1, Arthur Lamouroux1, Suwen Zhao3,4, Dirk Tourwé1, Raymond C Stevens3,4, Roger D Cone2,5, Steven Ballet1.
Abstract
The melanocortin receptors (MC1R-MC5R) belong to class A G-protein-coupled receptors (GPCRs) and are known to have receptor-specific roles in normal and diseased states. Selectivity for MC4R is of particular interest due to its involvement in various metabolic disorders, including obesity, feeding regulation, and sexual dysfunctions. To further improve the potency and selectivity of MC4R (ant)agonist peptide ligands, we designed and synthesized a series of cyclic peptides based on the recent crystal structure of MC4R in complex with the well-characterized antagonist SHU-9119 (Ac-Nle4-c[Asp5-His6-DNal(2')7-Arg8-Trp9-Lys10]-NH2). These analogues were pharmacologically characterized in vitro, giving key insights into exploiting binding site subpockets to deliver more selective ligands. More specifically, the side chains of the Nle4, DNal(2')7, and Trp9 residues in SHU-9119, as well as the amide linkage between the Asp5 and Lys10 side chains, were found to represent structural features engaging a hMC4R/hMC3R selectivity switch.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33190475 DOI: 10.1021/acs.jmedchem.0c01620
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446